China
METiS TechBio’s AI-Designed MTS-004 Meets Phase III Success in China, Targeting Pseudobulbar Affect
MTS-004 Poised to Fill an Unmet Need in the Treatment of Pseudobulbar Affect (PBA) METiS TechBio, a global leader in AI-driven nanodelivery and formulatio...
October 24, 2025 | News
Forlong Biotechnology and Henlius Join Forces to Develop Targeted Cytokine-Based Cancer Immunotherapy
Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, toda...
October 23, 2025 | News
SunRock Biopharma and Chime Biologics Partner to Advance Novel Anti-CCR9 Antibody Therapy for Inflammatory Bowel Disease
SunRock Biopharma, a biotechnology company focused on developing next-generation therapeutic antibodies, and Chime Biologics, a global leading contrac...
October 22, 2025 | News
Alphamab Oncology and CSPC’s HER2-Targeting ADC JSKN003 Receives Breakthrough Therapy Designation in China for Advanced Colorectal Cancer
Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targ...
October 21, 2025 | News
Sichuan Kelun-Biotech’s Trastuzumab Botidotin Approved in China for HER2-Positive Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's human epidermal growth factor recep...
October 20, 2025 | News
Merck Presents Longer-Term Phase 3 Data Showing Pimicotinib Achieves 76.2% Objective Response Rate in TGCT
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2% Global Phase 3 MANEUVER study de...
October 20, 2025 | News
Jacobio Pharma Partners with Oceanpine Capital in RMB 200 Million Equity Deal for Cardiovascular Research Subsidiary
Jacobio Pharma announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. ("Beijing Jacobio"), has entered into a Capital Increase and Equity...
October 16, 2025 | News
Clover Biopharmaceuticals Reports Promising Phase I Results for RSV+hMPV±PIV3 Combination Vaccines
Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously...
October 15, 2025 | News
Mabwell’s CDH17-Targeting ADC 7MW4911 Receives NMPA IND Clearance for Advanced Solid Tumours
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D cod...
October 15, 2025 | News
Everest Medicines Secures Dual IND Approvals for EVM14, Its First Internally Developed Therapeutic mRNA Cancer Vaccine
EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receive IND approvals from both China's National Medic...
October 14, 2025 | News
Lundbeck’s Bexicaserin Receives Breakthrough Therapy Designation in China for Severe Childhood Epilepsies
Accelerated pathway underscores urgent need for innovative solutions for patients with devastating, childhood-onset epilepsies Novel 5HT2C mechanism des...
October 14, 2025 | News
Thousand Oaks Biologics Secures EU QP Declaration for ADC Manufacturing Facility in Shanghai
Thousand Oaks Biologics' antibody-drug conjugate (ADC) manufacturing site successfully passed an audit conducted by a European Union Qualified Person ...
October 14, 2025 | News
Henlius’ HANSIZHUANG Meets Primary Endpoint in Phase 3 Gastric Cancer Trial
The phase 3 clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its EFS primary endpoint, supporting an early New Drug Applicati...
October 13, 2025 | News
C-Ray Therapeutics Commends Biokin on NMPA Approval for Groundbreaking [177Lu]-BL-ARC001 Radiopharmaceutical
C-Ray Therapeutics (Chengdu) Co.,Ltd proudly congratulates its strategic partner, Biokin Pharmaceutical, on receiving implied approval from the N...
October 13, 2025 | News
Most Read
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
